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Sir: 30 
 31 
In a human embryo it takes 8 weeks after fertilisation for the skeleton to begin to form, one of the 32 
last organs to develop before becoming a foetus. Mesenchymal progenitors, derived from neural 33 
crest cells, differentiate into chondrocytes where the skeleton is generated as a mostly cartilage 34 
template. Other mesenchymal progenitors envelop the template, activate runt related transcription 35 
factor 2 (RUNX2) and bone morphogenetic protein 2 (BMP2) and differentiate into osteoblasts, 36 
where an osteoid matrix is secreted and subsequently mineralised to become bone.1 During 37 
development and up to late adolescence, cellular proliferation enabling skeletal growth is restricted 38 
to the metaphysis and epiphyseal line or “growth plate”. It is in the growth plate of long bones 39 
where most bone cancers develop, hence the predominantly childhood incidence of the cancer. 40 
Primitive mesenchymal cells undergo transformation to form a heterogeneous group of bone 41 
malignancies. The most common type of bone cancer in children is osteosarcoma, mostly initiated 42 
by tumour protein p53 (TP53) mutations. The second most common type of bone cancer in children 43 
is Ewing sarcoma, mostly initiated by a EWS RNA binding protein 1-Fli-1 proto-oncogene, ETS 44 
transcription factor (EWSR1-FLI1) fusion. There are an average of 160 and 55 new cases of 45 
osteosarcoma and Ewing sarcoma, respectively, every year in the UK. Five-year survival for both 46 
cancer types is 50% when diagnosed early. Five-year survival is 15% when lung metastases are 47 
present at diagnosis. Treatment progress for bone cancer is poor when compared to other cancers 48 
such as breast where there is a twenty-year survival of 70%. Bone cancer requires extensive and 49 
sometimes disabling multimodal treatment. Chemotherapy for osteosarcoma includes 50 
methotrexate, cisplatin and doxorubicin, which were developed in the 1940’s and 1970’s. 51 
Chemotherapy for Ewing sarcoma includes vincristine, ifosfamide and etoposide, which were 52 
developed in the 1960’s and 1980’s. If the tumour responds well to chemotherapy and 53 
radiotherapy, wide area resection or amputation is performed. New understanding of bone cancer 54 
biology leading to better diagnosis and better treatments is required. 55 
 56 
Transcriptomic analysis of bone cancer is lacking. Different RNA populations within cells are 57 
generally classified as coding and non-coding, i.e. whether they have protein coding potential. 58 
Messenger RNA (mRNA) molecules contain a start codon “AUG” encoding methionine at the 59 
beginning of an open reading frame. Non-coding RNA lack protein coding ability and usually exist 60 
within the cell without a start codon. Over 70% of known non-coding RNA are long non-coding 61 
RNA (lncRNA) that are classed by their >200 nucleotide (nt) length. LncRNA similarly to mRNA 62 
are transcribed by RNA polymerase II, have a 5’ cap and are polyadenylated. LncRNAs have a 63 
large diversity of roles including regulation of chromatin dynamics, enforcing imprinting and as 64 
microRNA inhibitors by acting as a microRNA “sponge”. LncRNAs are further classified based on 65 
their genomic localisation. Intergenic lncRNAs are named for their production from loci in between 66 
genes. Intronic lncRNAs are named for their production from mRNA introns. Sense lncRNA are 67 
named for their production from the sense strand of protein coding genes that overlap with an 68 
exon/intron. Antisense lncRNA are named for their production from the antisense strand of protein 69 
coding genes that overlap with an exon/intron. Another elusive class of non-coding RNA is the 70 
small nucleolar RNAs (snoRNAs). SnoRNAs are 60-170 nt in length and are classed as C/D box 71 
snoRNAs and H/ACA box snoRNAs. C/D box snoRNAs guide 2′-O-methylation of ribosomal and 72 
transfer RNA. H/ACA box snoRNAs guide pseudouridylation mostly in transfer RNAs. The majority 73 
of snoRNA are intronic. There is a recent interest in lncRNA and snoRNA and their role in cancer 74 
biology. We took a next generation sequencing and bioinformatics approach to evaluate lncRNA 75 
and snoRNA expression in bone cancer. 76 
 77 
We extracted RNA using the miRCURY RNA isolation kit (Exiqon) from two tissue specimens of 78 
osteoblastic osteosarcoma (patient ages 15 and 19, OS1 and OS2 respectively). OS1 had 79 
undergone treatment with cisplatin and doxorubicin prior to surgery (Figure 1A&E). OS2 had 80 
undergone treatment with methotrexate, cisplatin and doxorubicin prior to surgery (Figure 1B&F). 81 
We extracted RNA from one tissue specimen of Ewing sarcoma (patient age 6, ES) where the 82 
patient had undergone nine alternating cycles of vincristine, doxorubicin and cyclophosphamide in 83 
one cycle and ifosfamide and etoposide in another cycle prior to surgery (Figure 1C&G). We 84 
extracted RNA from one tissue specimen of a spindle cell sarcoma of bone (patient age 17, SCS) 85 
where the patient had not undergone systemic treatment (Figure 1G&H). We used publically 86 
available data for 4 control samples, which were obtained from long bone tissue derived from 87 
surgical reconstruction procedures (patient ages 11-13).2 Cancer RNA was stored at -80 oC. We 88 
generated cDNA libraries using the SENSE mRNA library prep kit (Lexogen). We performed 150 89 
bp paired end sequencing on the HiSeq 4000 Ultra High Throughput Sequencing System (Illumina) 90 
at the Earlham Institute, Norwich Research Park. 91 
 92 
Raw fastq files were converted to fasta format. Adapter sequences and reads <20 nt were trimmed 93 
using Trim Galore (www.bioinformatics.babraham.ac.uk/projects/trim_galore). Trimmed reads 94 
were aligned to the human genome (v.38) using HISAT2.3 The latest set of human non-coding 95 
RNAs were download from GENCODE (v.28) and Ensembl (v.92). Count matrix for lncRNAs and 96 
snoRNAs was created using Kallisto.4 LncRNA and snoRNA expression was compared between 97 
bone cancer and controls using the DESeq2 package available in R. We selected differentially 98 
expressed lncRNA and snoRNA according to log2 fold change ≥2, p value <0.05 and false 99 
discovery rate <5%. Hierarchical cluster analysis and principle component analysis investigating 100 
77% of variance shows distinct grouping between cancer and controls (Figure 1I&J).  101 
 102 
We report a H19 transcript, H19-203, is highly expressed in bone cancer (Table 1). H19 is a 103 
maternally expressed, paternally imprinted, embryonic lncRNA.5 H19 is a key mediator of sonic 104 
hedgehog (SHH) signalling in osteoblastic osteosarcoma.6 SHH ligand is a major embryonic 105 
morphogen and is later required for adult stem cell division. H19 is reciprocally imprinted and 106 
regulated with its neighbouring gene insulin like growth factor 2 (IGF2).5 We find a MEG3 transcript, 107 
MEG3-224, to have a low expression in OS1 and ES (44 reads and 91 reads, respectively, 108 
normalised data in GEO). MEG3-224 expression was high in OS2 and SCS (2,091 reads and 109 
1,616 reads, respectively, normalised data in GEO) (Table 1). MEG3 is a maternally expressed, 110 
paternally imprinted lncRNA with low expression correlating to a poor prognosis in osteosarcoma 111 
and other cancers.7 XIST-201 and XIST-204, products of X inactive specific transcript (XIST), were 112 
highly expressed in our cohort with OS1 and ES showing the highest expression in the cohort 113 
(Table 1). XIST, located on the X chromosome, has previously been reported as a poor prognostic 114 
marker in solid tumours.8 We also found high expression of HCP5-204 that has previously been 115 
linked to cancer progression via sponging of miR-22, miR-186 and miR-216a.9 MALAT1-203 and 116 
MALAT1-214, products of metastasis associated lung adenocarcinoma transcript 1 (MALAT1), 117 
were downregulated in this study (Table 1).  118 
 119 
We report 4 dysregulated snoRNAs in our bone cancer samples (Table 1). SNORD68, recruited 120 
by DExD box helicase 21 (DDX21) to enable 2’-O-methylation of residue U428 of the 18S 121 
ribosomal RNA (rRNA) sequence, was upregulated in each cancer type (Table 1). SNORD3B-1 122 
and SNORD3B-2, close paralogues of U3 snoRNA, guide site specific cleavage of rRNA during 123 
pre-rRNA processing.10 We report SNORD3B-1 and SNORD3B-2 are upregulated in bone cancer 124 
(Table 1). SNORD58B is reported to guide the 2'-O-methylation of residue G4198 of the 28S 125 
rRNA.11 We found SNORD58B was downregulated in our bone cancer samples (Table 1).  126 
 127 
RNA therapeutics are on the horizon. LncRNA and snoRNA are of recent interest because of their 128 
elusive roles in regulating gene expression and epitranscriptomic modification of pre-RNAs. RNA 129 
is also a specific biomarker, which is especially helpful in providing a robust diagnosis in rare and 130 
heterogeneous cancers. Bone cancers are historically difficult to diagnose and sub classify prior 131 
to surgery, which can delay the appropriate choice of neoadjuvant chemotherapeutic agents. H19 132 
expression after birth is linked to Beckwith Wiedemann Syndrome, which increases the likelihood 133 
of childhood cancer but not adult cancer. We find that H19-203 may be a specific biomarker for 134 
osteosarcomas involving SHH signalling. Patients may benefit from receiving targeted SHH 135 
inhibitors sonidegib or vismodegib that are currently used to treat basal cell carcinoma. We also 136 
find low MEG3-224 and high XIST-201/XIST-204 may be markers of poor prognosis and lower 137 
overall survival in patients, which we detect in 2 out of 4 patients. Upregulation of snoRNAs is 138 
consistent with the increased proliferative behaviour of cancer cells. SNORD68, SNORD3B-1 and 139 
SNORD3B-2 may be useful biomarkers in the future. Previous research has shown the EWSR1-140 
FLI1 chimeric transcript in Ewing sarcoma is sensitive to snoRNA loss of function due to changes 141 
in splicing, demonstrating a potential target for intervention in Ewing sarcoma cells through 142 
snoRNA activity.12 143 
 144 
A limitation of this study is the size of the cohort studied. Bone cancer is rare and donation to tissue 145 
banks is scarce. Our data highlights the value of being able to provide a specific tissue diagnosis 146 
in addition to identifying regulatory transcriptomic molecules that could be exploited for targeted 147 
therapy.  148 
 149 
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FIGURE 1 203 
 204 
 205 
 206 
Figure 1. Macroscopic and microscopic photographs of resected tumours used in this study. In 207 
the microscopic images, the black scale bar is 100 µM (a) osteoblastic osteosarcoma was 208 
diagnosed at biopsy. Patient underwent treatment with cisplatin and doxorubicin. On resection, a 209 
partly cream/grey focally haemorrhagic tumour is observed (b) H & E stain of a shows a 5% 210 
response to chemotherapy (minimal response). Examination is consistent with osteoblastic 211 
osteosarcoma (c) osteoblastic osteosarcoma was diagnosed at biopsy. Patient underwent 212 
treatment with methotrexate, cisplatin and doxorubicin. On resection, a focally gelatinous and 213 
haemorrhagic tumour is observed (d) H & E stain of b shows a 95% response to chemotherapy 214 
(excellent response). Examination is consistent with osteoblastic osteosarcoma (e) Ewing sarcoma 215 
was diagnosed at biopsy. Patient underwent nine alternating cycles of vincristine, doxorubicin and 216 
cyclophosphamide (cycle 1) and ifosfamide and etoposide (cycle 2). On resection, a lesion with 217 
extensive involvement of the medulla and cortex with periosteal elevation is observed (f) H & E 218 
stain of e shows a monomorphic population of small round blue cells with hyperchromatic and 219 
indistinct nuclei. Cells were positive for CD99 and S100. Cells were negative for CD3, CD20, CD45, 220 
CKMNF116, EMA, AE1/3, SMA, desmin and FLI1. EWSR1 gene rearrangement observed in 56/72 221 
nuclei. Examination is consistent with Ewing sarcoma (g) high grade sarcoma was diagnosed at 222 
biopsy. On resection, a pale cream/grey and destructive lesion with permeation into underlying 223 
bone is observed (h) H & E stain of g shows an infiltrative pattern of growth within the bone and 224 
extraosseous extension. Tumour cells were negative for CD30, CD31, CD34, CD45, CD99, 225 
CKMNF116, EMA, AE1/3, SMA, desmin, S100, HMB45, STAT6, TLE1, Melan-A, CCNB3 and 226 
ALK1. There is no EWSR1-NR4A3 gene rearrangement. Examination is consistent with spindle 227 
cell sarcoma of bone (i) heat map based hierarchical cluster analysis of differentially expressed 228 
non-coding RNAs (y-axis) between bone cancer, OS1, OS2, ES, SCS and controls (x-axis). Z 229 
score refers to high (in red) and low (in blue) non-coding RNA expression using normalised values 230 
when compared to the mean of total sequencing reads (j) a biplot principle component analysis 231 
shows two distinct clusters along the PC1 axis that correspond to the bone cancer samples (in 232 
orange) and control samples (in blue).  233 
 234 
 235 
 236 
 237 
Table 1. The 10 most upregulated and 10 most downregulated lncRNA in our bone cancer cohort 238 
when compared to control samples. We also show 4 dysregulated snoRNAs. Differentially 239 
expressed lncRNA and snoRNA were identified according to log2 fold change ≥2, p value <0.05 240 
and FDR <5%. The full data set is publically available on GEO under accession GSE113916.  241 
 242 
Transcript ID 
Human Genome 
Annotation 
Type 
Dysregulation 
(up / down) 
Log2 Fold 
Change 
ENST00000617687.1 AC244100.2-202 antisense lncRNA up 13.22 
ENST00000414790.6 H19-203 intronic lncRNA up 12.9 
ENST00000535913.2 SLC12A5-AS1 antisense lncRNA up 12.69 
ENST00000554639.5 MEG3-224 intergenic lncRNA up 12.45 
ENST00000429829.5 XIST-204 intergenic lncRNA up 11.28 
ENST00000534150.5 AP000757.1-201 antisense lncRNA up 10.97 
ENST00000541196.2 HCP5-204 sense lncRNA up 10.7 
ENST00000404665.3 TMEM51-AS1 antisense lncRNA up 10.5 
ENST00000416330.1 XIST-201 intergenic lncRNA up 10.43 
ENST00000618234.4 AL034397.3-201 antisense lncRNA up 10.4 
ENST00000618925.1 MALAT1-214 intergenic lncRNA down 10.85 
ENST00000510859.5 PAX8-AS1-209 antisense lncRNA down 9.94 
ENST00000587245.2 PRMT5-AS1-203 antisense lncRNA down 9.88 
ENST00000544868.2 MALAT1-203 intergenic lncRNA down 9.5 
ENST00000637700.1 MIR100HG-224 intergenic lncRNA down 9.35 
ENST00000468186.5 THUMPD3-AS1-202 antisense lncRNA down 9.12 
ENST00000412059.5 GAS5-201 intronic lncRNA down 7.44 
ENST00000620594.1 ZFAS1-209 antisense lncRNA down 7.2 
ENST00000512932.5 THAP9-AS1-211 antisense lncRNA down 6.53 
ENST00000534782.3 MIR100HG-222 intergenic lncRNA down 6.5 
ENST00000363214.1 SNORD68 C/D box snoRNA up 4.02 
ENST00000577988.2 SNORD3B-1 C/D box snoRNA up 2.86 
ENST00000571722.3 SNORD3B-2 C/D box snoRNA up 2.68 
ENST00000607313.1 SNORD58B C/D box snoRNA down 2.28 
 243 
